Benefits of direct high-throughput cell counting in immuno-oncology research

Antibody-directed and drug therapies have been on the forefront of immuno-oncology research in the past 15 years. Since the FDA introduced the Breakthrough Therapy Designation in 2016 for novel promising drug therapies, the number of applicants and approved candidates has increased dramatically. As more and more researchers are looking at drug effects in cancer cells and moving forward in drug discovery, they face many challenges in their day to do work. Performing cell cytotoxicity assays for multiple cell lines with single and combination drug therapies is standard practice in immuno-oncology. While many researches use end-point assays such as MTT, XTT, WST, or CellTiter-Glo, others prefer the manual [...]

Cellometer T4 supports research into the chemoprotective effects of aspirin in a variety of cancer cell lines

South Dakota State researchers investigated the role aspirin and its primary metabolite salicylic acid play as chemoprotective agents via the inhibition of cell cycle regulators cyclin A2 and CDK2. Using a variety of human cancer cell lines (HCT 116, HT-29, SW480, SK-MEL-28, SK-MEL-5, MDA-MB-231, MCF7, NCI-H226, OVCAR-3, PC-3, and B16-F10), the scientists investigated the effects the drugs had on cyclin A2 and CDK2 levels and activity. Floating and trypsinized cells were collected and analyzed for viability with Trypan Blue and the Cellometer Auto T4. In all the cell lines examined, aspirin and salicylic acid down regulated cyclin A2 and CDK2 [...]

Celigo evaluates quinomycin A as a possible therapeutic tool for pancreatic cancer

The Notch-disrupting and cancer stem cell-inhibiting effects of the drug quinomycin A were investigated at the University of Kansas Medical Center. Using human pancreatic cancer cells PanC-1, MiaPaCa-2, and BxPC-3 and the Celigo to determine the number and size of pancreatospheres, researchers evaluated the drug’s ability to block cancer stem cell growth via inhibition of the Notch signaling pathway. After administration of the drug, proliferation and colony formation were blocked in cancer cell lines but not in normal pancreatic epithelial cells. Furthermore, cancer stem cell markers were reduced as was pancreatosphere formation. This work identifies quinomycin A as an efficacious [...]

By | 2018-06-11T14:49:57+00:00 January 26th, 2016|Categories: Celigo User Publications|Tags: , |0 Comments

Celigo evaluates a plant extract for glioblastomoa multiforme treatment

At the Canary Center at Stanford for Early Cancer Detection, investigators studied how AshwaMAX (a steroidal lactone from a winter cherry plant, Withania somnifera, extract) might work as an oral treatment for those with the highly aggressive cancer glioblastoma multiforme (GBM). A heterogeneous disease, non-specific therapies for GBM have proven largely ineffective. Two patient-derived GBM lines (GBM2, GBM39) and one GBM cell line were cultured to create neurospheres that were then exposed to various concentrations of AshwaMAX.  Celigo measured cell proliferation and cell death via Trypan Blue staining. AshwaMAX inhibited the neurospheres at nanomolar concentrations. After additional work in vivo, [...]

Cellometer investigates new treatment paradigm for advanced endometrial cancer

University of North Carolina researchers investigated different techniques for inhibiting the catalytic activity of protein hTERT – a marker of advanced stage endometrial cancer. Endometrial cancer cell lines ECC-1 and Ishikawa were exposed to either siRNA or a small molecule pharmacological inhibitor BIBR1532, in addition to the drug paclitaxel, to see whether inhibiting hTERT provided additional efficacy against these cancer cells. The Cellometer, in combination with propidium iodide and Annexin-V FITC, calculated apoptosis in the various treatment conditions. The hTERT inhibition plus paclitaxel did prove synergistic, reducing cell growth and invasion more than paclitaxel alone. Furthermore, BIBR1532 antagonized cell invasion [...]

Celigo Advances studies in T Cell Therapy as a pediatric CHOP patient defeats her recurrent leukemia with immunotherapy

Emily Whitehead, cancer survivor, holding Nexcelom cell counting sheep. Thanks to the lifesaving T cell therapy clinical trial at Children’s Hospital of Philadelphia, Emily Whitehead is now two years cancer free. Diagnosed with acute lymphoblastic leukemia (ALL) right after her 5th birthday, doctors discovered that Emily’s leukemia was particularly resistant to chemotherapy, as are roughly 15% of the total number of ALL cases. After two recurrences of the disease, Emily’s parents enrolled her in a clinical trial for CTL019, an experimental therapeutic using a patient’s own reprogrammed T cells to eliminate the cancer cells. Now 9 years old, [...]

Cellometer K2 aids in Anti-Cancer Immunity Research

The MD Anderson Cancer Center investigated how a patient’s anti-cancer T cells might be better protected from the cytotoxic effects of the anti-thymidylate drugs (AThys; such as methotrexate) used to treat lung, breast, colon, and pancreas cancers. Although AThys successfully attack cancer cells, the drugs also reduce a patient’s own anti-cancer T cell population, which plays an important role in helping the patient overcome the disease. Using Jurkat, AaPC cells, and mutated human proteins called muteins, researchers were able to manufacture T cells that were resistant to cytotoxic levels of AThys. The Cellometer K2 and Trypan Blue were used to [...]

Nexcelom has performed Cellometer image cytometry on all NCI-60 cancer cell lines

The ability to measure cell size has been a valuable tool for researchers examining the effects of pharmacological agents on cancer cells. Many of the NCI-60 cancer cell lines have distinctly different morphological features and cell sizes. Nexcelom has performed Cellometer image cytometry analysis on all NCI-60 cancer cell lines. Every cell sample was individually stained with Trypan blue, imaged and analyzed using Cellometer T4. Each sample was assessed for viability and cell size. Download Excel Table: Cell size distribution for all 60 NCI cancer cell lines The ability to accurately measure cell viability and cell size are two important [...]

By | 2014-01-13T09:37:43+00:00 January 13th, 2014|Categories: Cellometer Application News|Tags: , , |0 Comments